NEW YORK, Feb. 18, 2016 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of MannKind Corp. securities (NASDAQ:MNKD) from August 10, 2015 through January 5, 2016, all dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for MannKind investors under the federal securities laws.
To join the MannKind class action, go to the firm’s website at http://rosenlegal.com/cases-808.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) contrary to Defendants’ assurances, the mandated pulmonary testing or spirometry was still a significant issue impeding sales of Afrezza; and (2) as a result, Defendants’ statements about MannKind’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 15, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-808.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
FDA Approves Mitapivat for Anemia in Thalassemia Patients
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 



